CRTH2 Antibody
| Code | Size | Price |
|---|
| PSI-4027-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4027-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
CRTH2 Antibody: DP2, DL1R, CD294, CRTH2, GPR44, Prostaglandin D2 receptor 2, Chemoattractant receptor-homologous molecule expressed on Th2 cells
Application Note:
CRTH2 antibody can be used for detection of CRTH2 by Western blot a 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
CRTH2 Antibody: The chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) is a recently identified receptor for the prostaglandin D2 (PGD2) in addition to the classic prostaglandin D receptor. CRTH2 is expressed on Th2 cells and eosinophils and mediates chemotaxis of these cells to PGD2 and is thus thought to be a key receptor mediating eosinophil and Th2 recruitment during allergic responses. However, CRTH2-null mice showed enhanced eosinophil recruitment into the lung consistent with observations that the CRTH2-null mice produced significantly higher amounts of interleukin-5 (IL-5) and IL-3. This suggests that CRTH2 plays a nonredundant role in restricting eosinophilia and allergic response in vivo.
Background References:
- Nagata K, Hirai K, Tanaka K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999; 459:195-9.
- Shichijo M, Sugimoto H, Nagao K, et al. Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockage abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats. J. Pharmacol. Exp. Ther. 2003; 307:518-25.
- Chevalier E, Stock J, Fisher T, et al. Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J. Immunol. 2005; 2056-60.
Buffer:
CRTH2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
CRTH2 antibody was raised against a 18 amino acid synthetic peptide from near the amino terminus of human CRTH2.
The immunogen is located within the first 50 amino acids of CRTH2.
The immunogen is located within the first 50 amino acids of CRTH2.
NCBI Gene ID #:
11251
NCBI Official Name:
prostaglandin D2 receptor 2
NCBI Official Symbol:
PTGDR2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 43, 55 kDa
Observed: 60 kDa
Observed: 60 kDa
Protein Accession #:
NP_004769
Protein GI Number:
153791424
Purification:
CRTH2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology
SPECIFICITY:
At least two different isoforms of CRTH2 are known to exist; this antibody will detect both isoforms.
Swissprot #:
Q9Y5Y4
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | CRTH2 Peptide | PSI-4027P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|